These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36208569)

  • 1. Epigenetic potentiation of somatostatin-2 by guadecitabine in neuroendocrine neoplasias as a novel method to allow delivery of peptide receptor radiotherapy.
    Evans JS; Beaumont J; Braga M; Masrour N; Mauri F; Beckley A; Butt S; Karali CS; Cawthorne C; Archibald S; Aboagye EO; Sharma R
    Eur J Cancer; 2022 Nov; 176():110-120. PubMed ID: 36208569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study protocol of LANTana: a phase Ib study to investigate epigenetic modification of somatostatin receptor-2 with ASTX727 to improve therapeutic outcome with [177Lu]Lu-DOTA-TATE in patients with metastatic neuroendocrine tumours, UK.
    Murphy R; Chander G; Martinez M; Ward C; Khan SR; Naik M; Barwick T; Aboagye E; Sharma R
    BMJ Open; 2023 Oct; 13(10):e075221. PubMed ID: 37879695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulation of Somatostatin Receptor Type 2 Improves 177Lu-DOTATATE Therapy in Receptor-Deficient Pancreatic Neuroendocrine Tumor Model.
    Sharma R; Earla B; Baidoo KE; Zeiger MA; Madigan JP; Escorcia FE; Sadowski SM
    Mol Cancer Ther; 2023 Sep; 22(9):1052-1062. PubMed ID: 37487000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic drugs in somatostatin type 2 receptor radionuclide theranostics and radiation transcriptomics in mouse pheochromocytoma models.
    Ullrich M; Richter S; Liers J; Drukewitz S; Friedemann M; Kotzerke J; Ziegler CG; Nölting S; Kopka K; Pietzsch J
    Theranostics; 2023; 13(1):278-294. PubMed ID: 36593963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of 5-Fluorouracil with Epigenetic Modifiers Induces Radiosensitization, Somatostatin Receptor 2 Expression, and Radioligand Binding in Neuroendocrine Tumor Cells In Vitro.
    Jin XF; Auernhammer CJ; Ilhan H; Lindner S; Nölting S; Maurer J; Spöttl G; Orth M
    J Nucl Med; 2019 Sep; 60(9):1240-1246. PubMed ID: 30796167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multimodal Imaging of 2-Cycle PRRT with
    Albrecht J; Exner S; Grötzinger C; Prasad S; Konietschke F; Beindorff N; Kühl AA; Prasad V; Brenner W; Koziolek EJ
    J Nucl Med; 2021 Mar; 62(3):393-398. PubMed ID: 32859703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA-PKcs inhibitors sensitize neuroendocrine tumor cells to peptide receptor radionuclide therapy
    Reuvers TGA; Verkaik NS; Stuurman D; de Ridder C; Groningen MCC; de Blois E; Nonnekens J
    Theranostics; 2023; 13(10):3117-3130. PubMed ID: 37351169
    [No Abstract]   [Full Text] [Related]  

  • 8. Enhancing the anti-tumour activity of
    Cullinane C; Waldeck K; Kirby L; Rogers BE; Eu P; Tothill RW; Hicks RJ
    Sci Rep; 2020 Jun; 10(1):10196. PubMed ID: 32576907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of
    Shah RG; Merlin MA; Adant S; Zine-Eddine F; Beauregard JM; Shah GM
    Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33435224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applying HDACis to increase SSTR2 expression and radiolabeled DOTA-TATE uptake: from cells to mice.
    Klomp MJ; van den Brink L; van Koetsveld PM; de Ridder CMA; Stuurman DC; Löwik CWGM; Hofland LJ; Dalm SU
    Life Sci; 2023 Dec; 334():122173. PubMed ID: 37907154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating hsa-miR-5096 predicts
    Bocchini M; Tazzari M; Ravaioli S; Piccinini F; Foca F; Tebaldi M; Nicolini F; Grassi I; Severi S; Calogero RA; Arigoni M; Schrader J; Mazza M; Paganelli G
    Front Oncol; 2023; 13():1136331. PubMed ID: 37287922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural modifications toward improved lead-203/lead-212 peptide-based image-guided alpha-particle radiopharmaceutical therapies for neuroendocrine tumors.
    Lee D; Li M; Liu D; Baumhover NJ; Sagastume EA; Marks BM; Rastogi P; Pigge FC; Menda Y; Johnson FL; Schultz MK
    Eur J Nucl Med Mol Imaging; 2024 Mar; 51(4):1147-1162. PubMed ID: 37955792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
    Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of
    Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
    J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wnt/β-catenin modulating drugs regulate somatostatin receptor expression and internalization of radiolabelled octreotide in neuroendocrine tumor cells.
    Weich A; Rogoll D; Peschka M; Weich W; Pongracz J; Brand M; Fröhlich M; Serfling SE; Rowe SP; Kosmala A; Reiter FP; Meining A; Werner RA; Scheurlen M
    Nucl Med Commun; 2023 Apr; 44(4):259-269. PubMed ID: 36804512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug Development in Neuroendocrine Tumors: What Is on the Horizon?
    Garcia-Alvarez A; Hernando Cubero J; Capdevila J
    Curr Treat Options Oncol; 2021 Mar; 22(5):43. PubMed ID: 33786683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is There an Additional Value of Using Somatostatin Receptor Subtype 2a Immunohistochemistry Compared to Somatostatin Receptor Scintigraphy Uptake in Predicting Gastroenteropancreatic Neuroendocrine Tumor Response?
    van Adrichem RC; Kamp K; van Deurzen CH; Biermann K; Feelders RA; Franssen GJ; Kwekkeboom DJ; Hofland LJ; de Herder WW
    Neuroendocrinology; 2016; 103(5):560-6. PubMed ID: 26536001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
    Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
    J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy.
    Capello A; Krenning E; Bernard B; Reubi JC; Breeman W; de Jong M
    Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1288-95. PubMed ID: 16021448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin and dopamine receptor expression in neuroendocrine neoplasms: correlation of immunohistochemical findings with somatostatin receptor scintigraphy visual scores.
    Diakatou E; Alexandraki KI; Tsolakis AV; Kontogeorgos G; Chatzellis E; Leonti A; Kaltsas GA
    Clin Endocrinol (Oxf); 2015 Sep; 83(3):420-8. PubMed ID: 25808161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.